Home|Journals|Articles by Year|Audio Abstracts

Original Research

Bevacizumab with paclitaxel and carboplatin for locally advanced (Stage IIIB) metastatic adenocarcinoma of lung: A feasibility study from tertiary care center

Anjan Bera, Shatarupa Dutta, Linkon Biswas, Aparajita Sadhya.


Background: Lung cancer is the most common cancer and leading cause cancer-related death in worldwide and also in India. Around 42% of these patients have adenocarcinoma. Most of these patients presented in locally advanced stage or metastatic disease. There is no significant difference in effectiveness among different chemotherapy regimens with median survival of 8 months only. Hence, additional treatment option including newer monoclonal antibodies is needed to improve tumor control and survival. Vascular endothelial growth factor (VEGF) is critical determinant of tumor angiogenesis, a process that is necessary component of tumor growth, invasion, and metastasis. Bevacizumab (Bev), a humanized monoclonal antibody (IgG1) targeting VEGF, effective in colorectal cancer, renal cell carcinoma, glioblastoma multiforme, and non-small cell lung cancer and approved for clinical use since 2004.

Objectives: The aim of our study is feasibility of the combination of Bev with paclitaxel and carboplatin in locally advanced (Stage IIIB) metastatic adenocarcinoma of lung in our institute, N.R.S. Medical College and Hospital, Kolkata.

Materials and Methods: Between February 2015 and December 2018, ninety-eight previously untreated patients with locally advanced metastatic (Stages IIIB and IV) adenocarcinoma of lung treated with Bev with paclitaxel and carboplatin. Paclitaxel at a dose of 175 mg/m2, carboplatin at an AUC 6 mg/ml/min, and Bev at a dose of 15 mg/kg given on the 1st day of chemotherapy. Chemotherapy administered every 3 weeks up to 6 cycles with maintenance Bev until disease progression or unacceptable toxicity whichever is earlier. Patients ECOG 2 or more, brain metastasis, squamous cell histology, and hemoptysis were not included in the study.

Results: The Median overall survival (OS), progression free survival (PFS) were 9.4 and 5.2 months, respectively. Anemia (19%) and neutropenia (16 %) are most common toxicity.

Conclusion: Bev with paclitaxel and carboplatin in selected patients with adenocarcinoma of lung is safe and confers survival benefit with acceptable toxicity.

Key words: Bevacizumab; Paclitaxel; Carboplatin; Adenocarcinoma; Toxicity

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.